Abstract:Cabozantinib (CABOMETYX, Exelixis, Inc.) was recently approved by the US Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma in patients who have received prior antiangiogenic therapy. The approval was based on a randomized study in which patients with advanced renal cell carcinoma, who had received a prior anti-angiogenic therapy, received either cabozantinib (60 mg orally once daily; N = 330) or everolimus (10 mg orally once daily; N = 328) [Approved drugs 2016]. There is increasing evidence that cabozantinib alone or in combination with other medications will be used to treat other cancers and has shown potency and efficacy in clinical preliminary trials. The more potential cabozantinib has, the greater our understanding of cabozantinib-associated cell biology and toxicology profiles should be. Cell biology and toxicology (CBT) profiles mainly include drug efficacy-driven or associated molecular interactions, mechanisms, or adverse effects on cells (Gu and Wang 2016). Cabozantinib as a small molecule receptor tyrosine kinase inhibitor, primarily targets ret protooncogene (RET)-encoded receptor tyrosine kinase (RTK), mesenchymal epithelial transition factor (MET), and the vascular endothelial cell growth factor receptor 2 (VEGFR2), of which VEGFR2 is more sensitive. Approximately 60 RTK proteins act as high-affinity cell surface receptors for many polypeptide growth factors, cytokines, hormones, and as key regulators of physiological and pathophysiological cellular processes, through the transmembrane and/or non-transmembrane domains (Kano et al. 2016; Li and Hristova 2010). One of the most important factors to influenceCBTprofiles of cabozantinib is the specificity and affinity of RTK binding types and efficacies in various conditions. In addition to bind RET, MET, and VEGFR2, cabozantinib can also inhibit KIT, VEGFR3, TRKB, VEGFR1, AXL, TIE2, and FLT3, in order of the efficacy according to IC50 values. RTK is also known as tyrosine receptor kinase or tyrosine kinase receptor depending on the permutation and has about 17 classes/families involved in major biological function and signaling through the cell membrane. Treatment with cabozantinib decreased tumor and endothelial cell proliferation and growth and increased apoptosis in a number of cancers though the inhibition of MET and VEGFR2 phosphorylation (Yakes et al. 2011). It is also reasonable to postulate the inhibitory effects of cabozantinib on tumor growth through targeting multi-RTKs, of which some may be unexpected. The binding specificity of cabozantinib as the critical part of biological function not only alters drug efficacy and efficiency but also drug side effects and toxicity, in tissues and systems or drug resistance to protein kinase inhibitors. The development of uncontrolled adverse effects and drug resistance of cabozantinib is a potential risk and challenge for clinicians to pay special attention to during application, due to the complex interplay of cabozantinib with multiRTKs, even though clinical trials have demonstrated Cell Biol Toxicol (2016) 32:259–261 DOI 10.1007/s10565-016-9349-6

Characterization of genetic variation in CYP3A4 on the metabolism of cabozantinib in vitro.

Characterization of the metabolite of cabozantinib generated from liver microsomes and hepatocytes by ultra-high performance liquid chromatography coupled to quadrupole/orbitrap high resolution mass spectrometry

Functional Characterization of 27 CYP3A4 Protein Variants to Metabolize Regorafenib In Vitro.

Identification and Functional Assessment of EightCYP3A4Allelic Variants39–46Detected in the Chinese Han Population

Cabozantinib carries the risk of drug-drug interactions via inhibition of UDP-glucuronosyltransferase (UGT) 1A9.

Cabozantinib Carries the Risk of Drug-Drug Interactions Via Inhibition of UDPglucuronosyltransferase (UGT) 1A9

Effect of recombinant CYP3A4 variants and interaction on imatinib metabolism in vitro

Functional Characterization Of 22 Cyp3a4 Protein Variants To Metabolize Ibrutinib In Vitro

Cabozantinib Induces Isolated Hyperbilirubinemia in Renal Cell Carcinoma Patients carrying the UGT1A1*28 Polymorphism

Functional Characterization of Wild-Type and 24 Cyp2d6 Allelic Variants on Gefitinib Metabolism in Vitro

Functional Assessment of the Effects of CYP3A4 Variants on Acalabrutinib Metabolism in Vitro.

Functional evaluation of vandetanib metabolism by CYP3A4 variants and potential drug interactions in vitro

Cabozantinib Reverses Multidrug Resistance of Human Hepatoma HepG2/adr Cells by Modulating the Function of P‐glycoprotein

Functional characterization of 27 CYP3A4 variants on macitentan metabolism in vitro.

The Influence of CYP3A4 Genetic Polymorphism and Proton Pump Inhibitors on Osimertinib Metabolism

CBT Profiles of Cabozantinib Approved for Advanced Renal Cell Carcinomas

Genetic Polymorphisms of Cyclophophamide-Metabolizing Enzymes and Their Association with Chemotherapy Responses in Breast Cancer

Evaluation of Recombinant CYP3A4 Variants on the Metabolism of Oxycodone In Vitro

Functional Characterization of Five CYP2C8 Variants and Prediction of CYP2C8 Genotype-Dependent Effects on in Vitro and in Vivo Drug-Drug Interactions.

Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.

Structural and Functional Insights into CYP2C8.3: A Genetic Polymorph of Cytochrome P450 2C8